Results Healthcare has advised Novartis on the divestment of its Ringaskiddy, Ireland manufacturing facility

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs, Pharma & Biotech
  • Engagement Type: Sell Side
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility

Novartis has divested its Ringaskiddy campus to Sterling Pharma Solutions, a global contract development and manufacturing organisation, backed by Global Healthcare Opportunities (GHO Capital Partners LLP), the European specialist investor in global healthcare. The site currently manufactures a number of APIs across a range of therapeutic areas, and the deal includes an ongoing supply agreement between Sterling and Novartis from the Ringaskiddy facility.

The 111-acre facility, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well as facilities to support development and scale-up, complements Sterling’s core business focus and expands its global API manufacturing capabilities. The sale is expected to close in Q4 2022. Upon closing, the workforce will transition to Sterling.

This deal represents Results’ 6th deal advising Novartis over the past 2 years.

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to